Loading...
Kiaro Holdings Corp.
KIARF•PNK
Healthcare
Medical - Pharmaceuticals
$0.00
$0.00(0.00%)

Over the last four quarters, Kiaro Holdings Corp.'s revenue moved from $6.34M in Q4 2022 to $7.80M in Q3 2023. Operating income in Q3 2023 was -$3.07M, with a strong operating margin of -39%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Kiaro Holdings Corp. remained robust at -$3.38M, reflecting operational efficiency. Net income dropped to -$8.76M, with an EPS of -$0.33. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan